<DOC>
	<DOCNO>NCT02462330</DOCNO>
	<brief_summary>Stem cell therapy emerge treatment cardiovascular disease best cell type delivery method remain determine . Pre-clinical study demonstrate improvement cardiac function Mesenchymal stem cell ( MSC ) therapy particular paracrine immunosuppressive property . Investigators initiate MESAMI program bicentric pilot phase highlight safety feasibility intramyocardial injection MSCs bone marrow patient chronic ischemic cardiomyopathy leave ventricular dysfunction , guide NOGA-XP system . The MESAMI program continue phase 2 , multicenter , double-blind , randomize , placebo-controlled trial.The aim phase 2 study demonstrate functional improvement , measure peak VO2 , 3 month cell therapy group placebo group .</brief_summary>
	<brief_title>Administration Mesenchymal Stem Cells Patients With Chronic Ischemic Cardiomyopathy ( MESAMI2 )</brief_title>
	<detailed_description>Ischemic cardiomyopathy lead cause death men woman . During last decade , treatment heart failure evolve , purpose improve symptom prevent aggravation disease . Current research focus development cell-based therapy use different source stem cell provide trophic paracrine support even replace die cell new one . A specific form stem cell , call adult mesenchymal stem cell ( MSCs ) , show promise heart repair . These cell know ability secrete paracrine factor immunosuppressive property . The MESAMI 2 study evaluate efficacy MSCs injection directly heart repair restore heart function people chronic ischemic heart failure use NOGA-XP system . This phase 2 study prospective , multicenter , double-blind , randomize , placebo-controlled trial . A total 90 patient randomize 2 arm receive intramyocardial injection MSCs placebo . Patients follow 13 month . Bone marrow collect immediately transport French Blood Establishment MSC isolation expansion . Patients receive intramyocardial injection MSCs placebo leave heart catheterization .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Patient sign informed consent , Chronic stable ischemic cardiomyopathy least one month NYHA Class IIIV and/or Angina pectoris CCS Class III IV , Not candidate revascularization coronary artery bypass surgery angioplasty , Left ventricular function ≤45 % , Presence ischemia myocardial viability myocardial perfusion imaging , VO2 max≤ 20 ml/min/kg , Optimal medical therapy , Optimal interventional therapy ( Implantable Cardiovertor Defibrillator , effort rehabilitation ) . Exclusion criterion : Pregnancy breastfeeding , Acute coronary syndrome myocardial infarction last 3 month , Revascularization ( PCI CABG ) , cardiac resynchronization last 3 month , Further revascularization plan next 30 day , LVEF &gt; 45 % , Left intraventricular Thrombus / ventricular aneurysm detect transthoracic echocardiography , Wall thickness target region &lt; 8 mm determine echocardiography , Critical Limb Ischemia stag 3 4 , Inability achieve VO2 test , Not feasible peripheral arterial access percutaneous procedure , Aortic stenosis ( &lt; 1cm² ) aortic insufficiency ( &gt; 2 + ) , Patients transplant organ , Chronic renal failure creatinemia ≥ 250 µmol/L , Severe hepatic dysfunction , Chronic atrial fibrillation , Decompensated heart failure , Uncontrolled Ventricular arrhythmia , Indication cardiac resynchronization multisite pacemaker cardiac resynchronization last 3 month , Obesity prevent bone marrow aspiration manual compression puncture area bone marrow collection , Active uncontrolled infection Immunomodulator treatment ( ciclosporin , mycophenolate , mycophenolate mofetil , azathioprine , tacrolimus , anthracyclines , neupogen , hydrea , etanercept interferon , prednisolone , methylprednisolone , colchicine ) , History cancer last 5 year , Hemopathy , hematopoietic disease , Haemorrhagic syndrome , Chronic progressive disease may alter prognosis within 3 month , Positive serologies Human immunodeficiency virus ( HIV12 ) , HTLV1 ( human Tcell lymphotrophic virus ) 2 , HBV ( hepatitis B virus ) HCV ( hepatitis B virus ) . Allergic xylocain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>ischemic cardiomyopathy</keyword>
	<keyword>NogaStar XP system catheter</keyword>
</DOC>